Mycoplasma Testing Market for Cell Line Testing: Inside the 41.2% Application Leader
The mycoplasma testing market was valued at USD 1.1 billion in 2025 and is projected to reach USD 2.8 billion by 2033, growing at a CAGR of 12.0% from 2026 to 2033. Mycoplasma are tiny bacteria that pass through standard filters and quietly contaminate cell cultures. Every biologic, vaccine, and cell therapy batch therefore needs documented proof that they are absent. That non-negotiable requirement makes the mycoplasma testing market one of the steadiest niches in life-science quality control.
Mycoplasma Testing Market Overview & Growth Drivers
How Big Is the Market, and Where Is It Growing?
According to Grand View Research, the mycoplasma testing market is estimated at USD 1.3 billion in 2026, up from USD 1.1 billion in 2025. North America held the largest revenue share at 40.5% in 2025, with the U.S. as the biggest national market. Asia Pacific is expected to post the fastest CAGR through 2033.
Why Demand Keeps Rising
Growth in this market follows manufacturing investment. Each new biologics or vaccine facility creates a testing requirement from day one. Merck & Co. began construction on a USD 3 billion pharmaceutical manufacturing facility in Elkton, Virginia in October 2025. Merck also announced an investment above USD 338 million in April 2024 for a Life Science Center in Darmstadt, Germany. In July 2023 it invested roughly USD 25.85 million in Kansas to expand cell culture media production.
Regulators require manufacturers to show the absence of mycoplasma before product release. As cell and gene therapies move from trials to commercial scale, routine screening moves from optional to mandatory. Contamination can also ruin research results and cause costly production losses.
The figures in this article draw on Grand View Research’s market analysis. Continue your research with their Prism AI tool for more data and insights.
Restraints and the Speed Opportunity
High validation requirements are the main brake. Regulators expect proven sensitivity, specificity, accuracy, and reproducibility, which means expensive instruments, skilled staff, and documentation. Many smaller firms outsource testing rather than build in-house capability.
Speed is the biggest opportunity. Traditional culture-based methods need long incubation periods, while newer tools return results in hours or minutes:
- Sartorius launched a platform in June 2024 delivering results in under 90 minutes.
- MP Biomedicals’ Myco-Visible PCR Kit returns results within 3 hours.
- Fuse Diagnostics’ Flip Mycoplasma claims PCR-quality results in 12 minutes. It reached Europe through a distribution partnership with CliniSciences in August 2025.
CRISPR-based assays, NGS, and digital PCR are steadily replacing slower culture methods. In my analysis, compliance documentation is becoming as much of a differentiator as speed, because a fast result without validation support cannot be used in a regulated release decision.
Download a free sample report or claim your copy of this full market intelligence report
Mycoplasma Testing Market Segmentation Insights
By Product and Test Method
Kits and reagents accounted for the largest product share at 79.4% in 2025. They generate recurring consumable revenue from every installed instrument and every routine screening run. Services are expected to grow at the fastest CAGR. Contract testing, method validation, auditing, and training appeal to companies that would rather outsource than build capability. By test method, the integrated/automated segment led with a 41.5% share in 2025.
By Technology
PCR led the technology segment with a 47.5% share in 2025 and is also the fastest-growing technology, thanks to its sensitivity and speed. ELISA holds the second-largest share. It is sometimes combined with PCR as PCR-ELISA, which detects amplified mycoplasma DNA photometrically. Putting the two findings together, buyers appear to want molecular sensitivity wrapped in automation, so PCR leads technology while integrated/automated leads test method.
By Application and End Use
Cell line testing led applications with a 41.2% share in 2025 and the fastest growth, driven by expanding cell culture research. End-of-production cell testing ranked second. Pharmaceutical and biotechnology companies led end use with a 35.4% share in 2025 and the fastest CAGR. Contract research organizations are also expected to grow, since preclinical and biopharmaceutical development depend on sterile cultures.
Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs
By Region
North America’s lead reflects strict FDA guidance and a deep biopharma base. In September 2024, bioMérieux made method validation services available for its BIOFIRE Mycoplasma system through Bionique Testing Laboratories. In Asia Pacific, Japan’s Otsuka Pharmaceutical launched its Quick Navi-Mycoplasma Diagnostic Kit, and China’s stem cell research is expected to sustain demand. Latin America is led by Brazil, and the Middle East and Africa are seeing government-backed biotech expansion.
Key Industry Players in the Mycoplasma Testing Market
Grand View Research profiles these companies in its study:
- Thermo Fisher Scientific, Inc.
- Merck & Co., Inc.
- Lonza Group AG
- Charles River Laboratories International, Inc.
- PromoCell GmbH
The report separates these players into two groups. Thermo Fisher, Merck, Lonza, Charles River, Sartorius, and Eurofins compete on broad portfolios, global laboratory networks, and regulatory expertise that spans instruments, consumables, and services. The trade-off is that large structures can be slower on specialized niche needs. PromoCell, Asahi Kasei Medical, InvivoGen, and ATCC compete on focused expertise in cell culture quality, cell banks, and regenerative medicine research, though with smaller geographic reach.
Recent moves show where competition is heading. Thermo Fisher launched an enhanced qPCR assay in January 2024 validated for over 200 mycoplasma species, then allocated new funding in February 2025 for digital PCR-based rapid detection. Lonza is expanding its MycoAlert line with rapid detection technologies and announced its intent to acquire Redberry in October 2025.
Final Takeaway
The mycoplasma testing market grows with the biologics pipeline. Its recurring revenue sits in kits and reagents, its momentum in PCR and automation, and its future in rapid, validated, outsourced testing. With North America leading and Asia Pacific rising fastest, the market points toward USD 2.8 billion by 2033.
Check Out Our Dedicated Business Offerings –
U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Giochi
- Gardening
- Health
- Home
- Literature
- Music
- Networking
- Altre informazioni
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness